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Breast cancer is the most common malignancy among women in
developed countries. A family history of breast and/or ovarian
cancer is one of the main risk factors for the development of the
disease (Lynch et al, 1981). It is estimated that about 5–10% of
breast cancer cases may be due to inherited predisposition but the
exact number of predisposing genes is unknown. In the context
of high-risk families, epidemiological studies have provided
evidence of at least two susceptibility genes: BRCA1 (17q21)
(Miki et al, 1994) and BRCA2 (13q12) (Wooster et al, 1995). Early
estimates suggested that BRCA1 would be responsible for 45% of
site-specific breast cancer families and the majority of breast and
ovarian cancer families (Easton et al, 1993). These first studies
also suggested that BRCA2 might be responsible for 25–35% of
site-specific breast cancer and would be implicated in the majority
of male breast cancer families (Stratton et al, 1994). However,
recent data show that these percentages could have been over-
estimated and that the proportion of families with mutations in
BRCA1 or BRCA2 strongly depends on the population analysed
(Szabo and King, 1997) and the specific characteristics of the
families selected (Schubert et al, 1997; Serova et al, 1997; Ford
et al, 1998; Malone et al, 1998). These studies suggest that BRCA1
could account for only about 15% of inherited breast cancer and
about 45% of families with breast and ovarian cancer (Couch et al,
1997; Serova et al, 1997; Shattuck-Eidens et al, 1997).
In the present study we analyzed a group of 32 Spanish families
with three of more cases of women affected with breast cancer, at
least one of them diagnosed before the age of 50. The objective of
the study was to establish the proportion of cases attributable to
mutations in the BRCA1 or BRCA2 genes in our population and to
contribute to the general knowledge of the proportion of mutations
found in families with a modest cancer profile, which comprise the
majority of the families seeking genetic advice. Although the
percentage of mutations was low (25%), striking differences were
observed when families were classified attending to the presence
of ovarian cancer or male breast cancer. These results are useful to
establish a guideline in the development of mutation screening for
the BRCA genes.
PATIENTS AND METHODS
Breast/ovarian cancer families
Thirty-two breast and/or ovarian cancer families were selected
from women who underwent surgery in Fundación Jiménez Díaz
(Madrid) in the last 7 years. These families can be considered
representative of the Spanish population as a whole, as they are
ascertained in every area of the country. The selection criteria were
as follows:
1. Families with three or more cases of women affected with
breast cancer and at least one of them diagnosed before the age
of 50 (27 cases)
2. Families with three or more cases of women affected with
breast cancer and at least one case of male breast cancer diag-
nosed at any age (five cases).
Mutation detection
We performed a molecular analysis of the complete coding
sequence and exon–intron boundaries of the BRCA1 and BRCA2
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genes. For this study we used the PTT (protein truncation test),
SSCP (single-strand conformation polymorphism) and direct
sequencing methods.
PTT
We used this method for the analysis of exon 11 of the BRCA1
gene and exons 10 and 11 of the BRCA2 gene. Exons were ampli-
fied by polymerase chain reaction (PCR) in overlapping fragments
of 1000–2000 bp using primers previously described (Hogervost
et al, 1995; BIC website), which contained an T7 promoter, a
eukariotic translation initiation sequence and gene-specific
sequences. The PCR conditions were the following: 250 ng of
genomic DNA; 10 ´ PCR buffer (Boehringer Mannheim), a mix of
200 mM of dATP, dTTP, dGTP and dCTP; 40 pmol each primer
and 2.5 U of Taq polymerase (Boehringer Mannheim).
Approximately 1 mg of the PCR product was ‘in vitro’ transcribed
and translated using the TnTR T7 Quick Coupled
Transcription/Translation System from Promega. The proteins
were labelled with biotinilated lysine (Promega) and electro-
phoresed in a 12.5% polyacrylamide-sodium dodecyl sulphate
(SDS) gel. The detection was performed using the ‘Transcend™
Chemiluminescent Non-Radioactive Translation’ from Promega.
SSCP
SSCP was used for the analysis of exons 2–10 and 12–24 of the
BRCA1 gene, and 2–10 and 12–27 of the BRCA2 gene using primers
previously described (Simard et al, 1994; Stratton et al, personal
communication). Fragments of 200–300 bp were amplified under
standard PCR conditions containing 100 ng genomic DNA, 10 ´
PCR buffer (Boehringer Mannheim), a mix of 200 mM of dATP,
dTTP, dGTP and 10 mM of dCTP, 1 ml of 10–25 pmol each primer,
1.75 U of Taq polymerase (Boehringer Mannheim) and 0.5 mCi 32P
dCTP (INC). In some cases, 2% of dimethyl sulphoxide (DMSO)
and 0.1% of Triton X-100 were added to improve the amplification.
Amplification was performed in a Perkin-Elmer Cetus 2400 thermo-
cycler. PCR amplification conditions were as follows: 35 cycles of
denaturing at 94°C for 45 s, annealing for 30 or 45 s and in some
cases extension at 72° for 30 s. Reaction products were run in a
SSCP electrophoresis gel under two conditions (room temperature,
10 W; 4°C, 50 W). Suspected mutants were identified as having a
mobility shift.
Direct sequencing
All the variants found by both methods were sequenced to verify
the mutation. The DNA isolated from mutant allele carriers was
amplified by PCR and the products were purified using an EZNA
Cycle-pure kit (Labclinic). The purified DNA was subjected to
cycle sequencing using an automated fluorescence-based cycle
sequencer (Abi Prism 310, Perkin-Elmer) and dye terminator
system.
RESULTS
BRCA1 and BRCA2 mutations
Only three of the 22 site-specific female breast cancer families
were found to harbour mutations, one in the BRCA1 gene and two
in the BRCA2 gene (Table 1). The BRCA1 mutation identified was
a splice-site mutation previously described. The two families with
a BRCA2 mutation showed the same alteration, 936delAAAC in
exon 11, which is considered one of the recurrent mutations in the
BRCA2 gene (Neuhausen et al, 1998).
Two of five families with breast and ovarian cancer and no
males affected showed mutations in the BRCA1 gene. One was
a frameshift mutation in exon 3, 39delTG, not previously
described. The second alteration was an amino acid substitution in
exon 18 that was classified as a missense mutation, as it was found
in two affected sisters from the same family, but it was not
detected in 200 control chromosomes. This alteration would be
expected to be significant, since it results in the substitution of a
small hydrophobic amino acid by a hydrophilic-charged one, and
it is localized in the COOH terminal region of the gene which is
Table 1a BRCA1 mutations
Family Female breast Average Ovarian BRCA1 Exon Codon Effect
cancer age cancer mutation
M36 8 42.0 – 5272–1–G/A Intron 18 – Splicing
M72 4 (2B)a 38.6 3 5236GGA/GAA 18 1706 G1706E
M73 2 43.0 4 236delAG 3 39 Ter39
aB = bilateral breast cancer.
Table 1b BRCA2 mutations
Family Female breast Average Male breast Other cancersb BRCA2 Exon Codon Effect
cancer age cancer mutation
M21 4(2B) 44.5 – Pan, Hep, Lung, Int DelAAAC 11 936 Ter956
M22 4(3B) 44.7 3 Ov, Leu, Ut, Osteo, St Del5 23 3009 Ter3015
M24a 1 49.0 1 Ov (3), NHL, St DelAA 14 2370 Ter2390
M45 11 47.7 1 Ov DelAA 25 3104 Ter3109
M59 4 38.0 – Prostate delAAAC 11 936 Ter956
aFive paternal relatives affected by breast cancer at unknown ages and four relatives affected by other cancers. bPan = pancreatic cancer, Hep = hepatic
cancer, Int = intestine cancer, Leu = leukaemia, Ut = uterine cancer, Osteo = osteosarcoma, NHL = non-Hodgkin’s lymphoma, St = stomach cancer, Ov =
ovarian cancer.1268 A Osorio et al
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highly conserved and supposed to be functionally important (Abel
et al, 1995).
Three of five families with male breast cancer (60%), revealed
frameshift mutations in the BRCA2 gene (Table 1). All the families
with mutations also contained cases of ovarian cancer and in two
of them, there were several members affected by other types of
cancer.
Surprisingly, in the case of the BRCA1 gene we did not detect
any mutation in exon 11, which, to date, is supposed to accumulate
a great proportion of the mutations identified in most of the
studies. Our results are in agreement with those derived from other
studies in Spanish population (Baiget et al, personal communica-
tion; Caldés et al, personal communication). In the case of BRCA2,
the mutations identified were distributed between exon 11 and
exon 27. We found unknown significance variants in the BRCA2
gene in two families (Table 2): one of them (family 44), contained
three cases of female breast cancer and four additional members of
the family affected by tyroid, stomach, intestine and liver cancer,
the second case (family 68) contained three cases of female breast
cancer. We did not have enough data to accept or rule out the
implication of these variants in the pathology of the disease in
none of the cases. We also found a great number of polymorphisms
in both genes (Table 2).
Classification of families
Although the proportion of mutations was low considering all the
families (25%), the percentages were strongly modified when we
analysed different groups of families. We categorized the families,
according to the number of breast cancer cases, the presence of
ovarian cancer and the presence of male breast cancer (Table 3).
Table 2a Polymorphisms found in the BRCA1 gene
Varianta Exon Codon Amin acid Frequencyb
change
IVS8-57delT Intron 8 – – 16/54
4447T/C 13 1436 Ser-Ser 72/180
4956A/G 16 1613 Ser-Gly 6/50
5272+66G/A Intron 18 – – 17/54
aThe number indicates the nucleotide in which the alteration ocurrs. All the
variants have been previously described. bThe frequency is obtained by the
number of chromosomes which showed the variant/total number of
chromosomes analysed in our breast cancer population.
Table 2b Polymorphisms found in the BRCA2 gene
Variant Exon Codon Amino acid Frequency Frequency
change in control
population
CAG/CAA 2 – – 3/26 –
909+56C/T Intron 8 – – 2/26 –
AAT/CAT 10 289 Asn-His 1/32 4/112
TCA/TCG 10 470 Ser-Ser 1/24
AAA/AAGa 11 1132 Lys-Lys 2/22 19/80
AAA/GAAa 11 1286 Lys-Glu 9/26 3/116
AGC/AGT 11 1528 Ser-Ser 1/26 –
ACG/ATG 11 1915 Thr-Met 1/26 –
TCA/TCG 14 2414 Ser-Ser 3/24 –
AAT/AGTb 4 108 Asn/Ser 1/26 1/200
ACC/GCCb 27 3349 Thr/Ala 1/26 1/200
aPolymorphisms not previously described. bUnknown significant variants.
Table 3 Proportion of mutations in the BRCA1 and BRCA2 genes
Group of families No. of families BRCA1 BRCA2 Total proportion
mutations mutations of mutations
Breast site-specific cancer families
3–5 cases 18 – 11% (2) 11% (2)
> 5 cases 4 25% (1) – 25% (1)
Total 22 4.5% (1) 9% (2) 13.5% (3)
Breast and ovarian cancer families 5 40% (2) – 40% (2)
Male breast cancer families 5 – 60% (3) 60% (3)
All families 32 9.3% (3) 15.6% (5) 25% (8)BRCA1 and BRCA2 analysis 1269
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The lowest proportion of mutations was found in the site-
specific female breast cancer families (13.5%). In the breast and
ovarian cancer families the percentage of mutations was 40% and
all of them were found in the BRCA1 gene. In the case of male
breast cancer families, we found 60% of mutations and all of them
were found in the BRCA2 gene.
DISCUSSION
Although there are some BRCA1 and BRCA2 mutational studies in
the Spanish population, they are focused on women with sporadic
or early onset breast cancer (Garcia-Patino et al, 1998) or they are
limited to the analysis of possible recurrent mutations (Osorio
et al, 1998; Díez et al, 1999). The present study is the first one in
which the whole coding region of the BRCA1 and BRCA2 genes
are analysed in a group of selected breast and/or ovarian cancer
Spanish families. The proportion of mutations in the BRCA1 or
BRCA2 genes found in our 32 families was low (25%). These
results are in agreement with several recent studies that show how
the percentage of mutations found in the BRCA genes is much
lower than the predicted from the linkage studies. Most of the first
linkage and mutational analysis of familial breast cancer suggested
that mutations in the BRCA1 and BRCA2 genes together would
account for most of the high-risk breast and/or ovarian cancer
families (Easton et al, 1993). However, these studies were focused
on rare families with an extremely large number of affected
women. This and other studies evidence how the majority of fami-
lies attending genetic counselling show a modest cancer profile
and that it is important to establish the real implication of the
BRCA genes in this group (Ford et al, 1998; Malone et al, 1998).
The lowest percentage of mutations, 13.5%, was found in the
breast site-specific cancer families. Recent studies suggest that in
this types of family, BRCA1 mutations would account for only
10–20% of the cases and probably the same would be for BRCA2
(Blackwood & Weber, 1998). These studies suggest that most of
the families with five or fewer cases of women affected with breast
cancer and without any case of ovarian or male breast cancer
would be attributable to mutations in other low-penetrance suscep-
tibility genes distinct from BRCA1 and BRCA2 (Schubert et al,
1997; Serova et al, 1997; Ford et al, 1998; Malone et al, 1998); the
majority of our families contained 3–5 cases of breast cancer,
which explains the low proportion of mutations found.
In the group of breast and ovarian cancer families, the
percentage of mutations was 40% and all of them were found in
the BRCA1 gene. This proportion is identical to that found in the
last studies, in which up to 45% of breast and ovarian cancer fami-
lies turned out to be attributable to mutations in the BRCA1 gene
(Couch et al, 1997; Serova et al, 1997; Shattuck-Eidens et al,
1997). We did not find any relationship between the number of
breast cancer cases in the family or the existence of bilateral breast
cancer, and the presence of mutation, but this was probably due to
the small number of families analysed.
Sixty per cent of the families with at least one case of male
breast cancer harbour a mutation in the BRCA2 gene. This
percentage is high and similar to the found in other studies (Ford
et al, 1998), and shows once again the relationship which exists
between male breast cancer and mutations in the BRCA2 gene.
We observed a number of tumours other than breast and ovary,
in the BRCA2 families. This is in agreement with previous studies
that suggest that mutations in BRCA2 confer an increased risk for
different types of cancer. A recent work from the Breast Cancer
Linkage Consortium shows that pancreatic and prostate cancers
are the most frequent in BRCA2 families. In our case, we found
two families with one case each of prostate and pancreatic cancer,
but all the rest of the tumours observed were of different types.
It is important to note that up to 30% of the mutations can be
localized outside the coding region of the genes or consist of great
deletions or rearragements not detectable by conventional tech-
niques. On the other hand, we can find mutations that cause an
amino acid substitution whose effect in the protein function is
unknown. These variants cannot be considered as mutations but it
is not possible to rule out their role in the development of the
disease. We found unknown significance in variants in two of our
families. Although all these factors can contribute to the low
number of mutations detected, they are not supossed to strongly
affect the percentages.
In summary, our study confirms once again that the proportion
of mutations in the BRCA1 and BRCA2 genes in breast cancer
families is low, making the genetic testing and counselling
extremely difficult. However, the presence of at least one case of
ovarian cancer or male breast cancer is a strong predictor for the
presence of mutations in the BRCA1 and BRCA2 genes respec-
tively, which makes these kinds of family specially eligible for the
mutational studies.
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